BY
Bai, Yuxian
2 yayın · 431 atıf · 2023–2024
Yayın
2
Atıf
431
Yıllar
2
Yayınlar
| Başlık | Yıl | Tip | Atıf |
|---|---|---|---|
|
Pembrolizumab in HER2-Positive Gastric Cancer
|
2024 | Letter | 47 |
|
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial
|
2023 | Article | 384 |